No Data
China Merchants Securities: The "AI + Healthcare" TOC application is beneficial to the public, and leading enterprises are expected to benefit first.
The introduction of AI is expected to improve data accuracy and continuity (asia vets wearable devices for continuous data collection, in conjunction with patient hospital medical records), provide professional personalized health services (AI doctors/nurses), and create more possibilities (brain-computer interfaces offer assistance in movement and neurological rehabilitation, improving the quality of life for people with disabilities, etc.).
ClouDr's Digital Diabetes Product Gets Approval in China
ClouDr Group Launches AI-Driven Diabetes Drug
Zhiyun Health (09955.HK): Diabetes digital medication product ClouDT-01 has obtained the China medical instruments registration certificate.
Grants in September 26th | Zhiyun Health (09955.HK) announced that the company's independently developed diabetes digital pharmaceutical product ClouDT-01 has recently been approved by the Zhejiang Pharmaceutical Supervision Administration of China and has obtained its issued China Medical Device Registration Certificate (Zhejiang Device Registration No. 20242211785). The announcement stated that ClouDT-01 is an important product in the company's digital pharmaceutical research and development pipeline. Leveraging the company's advanced artificial intelligence large model, comprehensive diabetes service management database, and rich clinical experience in diabetes, the product adopts chain technology to deeply analyze the diagnosis and treatment of diabetes.
Hong Kong stocks anomaly | Zhixun Health rose over 7.8% at one point and held talks with French pharmaceutical company Ipsen to expand cooperation.
On September 25, HealthTech (9955.HK) once rose more than 7.8% during trading hours, reaching a peak of 1.24 Hong Kong dollars. Recently, HealthTech has held strategic cooperation talks with the French pharmaceutical company Ipsen. Building on the success of past collaborations, both parties exchanged ideas on expanding cooperation areas and enhancing cooperation outcomes. Since the collaboration began, leveraging the strong online and offline outreach capabilities and mature operational experience of HealthTech, Ipsen's flagship product Decapeptyl has achieved impressive market performance. Currently, based on both in-hospital and outpatient sectors.
CLOUDR: INTERIM REPORT 2024
No Data
No Data